BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $299.25.

A number of brokerages have weighed in on BGNE. Morgan Stanley dropped their target price on shares of BeiGene from $300.00 to $293.00 and set an “overweight” rating on the stock in a report on Friday, July 15th. JPMorgan Chase & Co. restated an “overweight” rating and set a $296.00 price target on shares of BeiGene in a research report on Tuesday, August 9th. Finally, StockNews.com upgraded shares of BeiGene from a “sell” rating to a “hold” rating in a research report on Monday, August 8th.

Insider Activity at BeiGene

In related news, CFO Julia Aijun Wang sold 295 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $158.50, for a total value of $46,757.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Lai Wang sold 458 shares of the firm’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $177.32, for a total transaction of $81,212.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Julia Aijun Wang sold 295 shares of the firm’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BeiGene

Several large investors have recently made changes to their positions in BGNE. Koshinski Asset Management Inc. boosted its position in shares of BeiGene by 139.6% during the 1st quarter. Koshinski Asset Management Inc. now owns 242 shares of the company’s stock valued at $46,000 after purchasing an additional 141 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of BeiGene during the 2nd quarter valued at about $65,000. Advisors Asset Management Inc. boosted its position in shares of BeiGene by 26.7% during the 1st quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company’s stock valued at $235,000 after purchasing an additional 262 shares in the last quarter. Desjardins Global Asset Management Inc. boosted its position in shares of BeiGene by 7.6% during the 2nd quarter. Desjardins Global Asset Management Inc. now owns 1,523 shares of the company’s stock valued at $246,000 after purchasing an additional 107 shares in the last quarter. Finally, Laurel Wealth Advisors Inc. purchased a new stake in BeiGene during the fourth quarter valued at about $249,000. Institutional investors own 51.77% of the company’s stock.

BeiGene Stock Down 3.2 %

Shares of NASDAQ:BGNE opened at $148.85 on Thursday. The stock has a market capitalization of $15.43 billion, a price-to-earnings ratio of -7.29 and a beta of 0.65. BeiGene has a 1-year low of $118.18 and a 1-year high of $396.26. The company’s fifty day moving average is $174.87 and its two-hundred day moving average is $168.02. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.35 and a current ratio of 4.54.

BeiGene (NASDAQ:BGNEGet Rating) last issued its earnings results on Thursday, August 4th. The company reported ($5.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.23) by ($1.33). The business had revenue of $341.57 million for the quarter, compared to analyst estimates of $297.28 million. BeiGene had a negative return on equity of 38.58% and a negative net margin of 187.65%. Equities analysts anticipate that BeiGene will post -17.02 EPS for the current year.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Stories

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.